{"disease":{"id":"alopecia-areata","name":"Alopecia Areata","therapeutic_area":"Dermatology","data":{"aiSummary":"The treatment landscape for alopecia areata is evolving, with current options including topical and intralesional corticosteroids. Recent advances include the development of JAK inhibitors, such as baricitinib and ritlecitinib, showing promising results in clinical trials. The pipeline includes other JAK inhibitors and potential antibody-drug conjugates, offering hope for improved efficacy and targeted therapies. The focus is on developing systemic treatments for more severe forms of alopecia areata, with the aim of achieving complete hair regrowth and improving patient quality of life.","drug_count":7,"description":"Alopecia Areata (AA) is an autoimmune disease characterized by non-scarring hair loss, affecting the scalp, face, and other body areas. The condition results from immune cells attacking hair follicles, leading to hair loss in patches or, in severe cases, complete hair loss. The pathophysiology involves T-cell mediated destruction of hair follicles, influenced by genetic and environmental factors. Current treatments aim to modulate the immune system and promote hair regrowth.","subtype_count":13},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.906Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":7,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"deuruxolitinib","indication_name":"Severe alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leqselvi","generic_name":"DEURUXOLITINIB","company_name":"Sun Pharm Inds Inc","drug_phase":"marketed","molecular_target":"JAK1, JAK2, TYK2","drug_class":"","quality_score":77,"revenue":"2600","mechanism":"Deuruxolitinib inhibits JAK1, JAK2, and TYK2, modulating cytokine and growth factor signaling involved in hematopoiesis and immune function."},{"drug_id":"deuruxolitinib","indication_name":"severe alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leqselvi","generic_name":"DEURUXOLITINIB","company_name":"Sun Pharm Inds Inc","drug_phase":"marketed","molecular_target":"JAK1, JAK2, TYK2","drug_class":"","quality_score":77,"revenue":"2600","mechanism":"Deuruxolitinib inhibits JAK1, JAK2, and TYK2, modulating cytokine and growth factor signaling involved in hematopoiesis and immune function."},{"drug_id":"baricitinib","indication_name":"Alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Olumiant","generic_name":"baricitinib","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase JAK2","drug_class":"Janus Kinase Inhibitor [EPC]","quality_score":50,"revenue":"1200","mechanism":""},{"drug_id":"ritlecitinib","indication_name":"Alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Litfulo","generic_name":"ritlecitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ITK/TSK","drug_class":"","quality_score":52,"revenue":null,"mechanism":"Litfulo works by blocking the activity of a specific enzyme called tyrosine-protein kinase ITK/TSK."},{"drug_id":"olumiant","indication_name":"Alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olumiant","company_name":"NHS Greater Glasgow and Clyde","drug_phase":"marketed","molecular_target":"Casein kinase I isoform gamma-1, Citron Rho-interacting kinase, Mitogen-activated protein kinase kinase kinase 1","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"triamcinolone","indication_name":"Alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone-hexacetonide","indication_name":"Alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aristospan","generic_name":"TRIAMCINOLONE HEXACETONIDE","company_name":"Ethypharm","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe alopecia areata in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06651600","indication_name":"Severe alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Litfulo","generic_name":"pf-06651600","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ITK/TSK","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Litfulo works by blocking the ITK/TSK enzyme, which helps to stop the immune system from attacking hair follicles."},{"drug_id":"pf-06651600","indication_name":"Alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Litfulo","generic_name":"pf-06651600","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ITK/TSK","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Litfulo works by blocking the ITK/TSK enzyme, which helps to stop the immune system from attacking hair follicles."},{"drug_id":"litfulo","indication_name":"Alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Litfulo","generic_name":"Ritlecitinib Tosylate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Janus kinase 3 (JAK3) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family","drug_class":"Kinase inhibitor","quality_score":63,"revenue":null,"mechanism":"Ritlecitinib irreversibly inhibits JAK3 and TEC kinase family by blocking ATP binding site."},{"drug_id":"ritlecitinib-20-mg","indication_name":"Moderate to severe alopecia areata","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ritlecitinib 20 mg","generic_name":"ritlecitinib-20-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK3/STAT3 pathway","drug_class":"small molecule inhibitor","quality_score":22,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":13,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05727306","title":"Healthcare Disparities in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":4052231,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT04239521","title":"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":51955,"lead_sponsor_name":"Momentum Data","has_results":false},{"nct_id":"NCT05084417","title":"A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"OM1, Inc.","has_results":false},{"nct_id":"NCT06283316","title":"Systemic Treatments for Alopecia Areata Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT05745389","title":"CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"CorEvitas","has_results":false},{"nct_id":"NCT07152119","title":"A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06562270","title":"CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"CorEvitas","has_results":false},{"nct_id":"NCT04006457","title":"Long-Term PF-06651600 for the Treatment of Alopecia Areata","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1057,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05928169","title":"Determinants of Chronic Inflammatory Skin Disease Trajectories","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University Hospital Schleswig-Holstein","has_results":false},{"nct_id":"NCT06531109","title":"Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib","phase":"","overall_status":"RECRUITING","enrollment_count":850,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03570749","title":"A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":784,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT03732807","title":"PF-06651600 for the Treatment of Alopecia Areata","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":718,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04518995","title":"Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":706,"lead_sponsor_name":"Concert Pharmaceuticals","has_results":true},{"nct_id":"NCT03899259","title":"A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":606,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT06873945","title":"A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":550,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04797650","title":"Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":517,"lead_sponsor_name":"Concert Pharmaceuticals","has_results":true},{"nct_id":"NCT06279221","title":"Litfulo Capsules Special Investigation","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":487,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03976622","title":"Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata","phase":"","overall_status":"UNKNOWN","enrollment_count":450,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT05051761","title":"Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":425,"lead_sponsor_name":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","has_results":false},{"nct_id":"NCT05041803","title":"European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":407,"lead_sponsor_name":"Sun Pharmaceutical Industries, Inc.","has_results":true},{"nct_id":"NCT06802705","title":"Psychosocial Stress on QOL in Saudi Arabian Patients With Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":398,"lead_sponsor_name":"University of Jeddah","has_results":false},{"nct_id":"NCT05470413","title":"Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":330,"lead_sponsor_name":"Reistone Biopharma Company Limited","has_results":false},{"nct_id":"NCT04784533","title":"A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":317,"lead_sponsor_name":"Concert Pharmaceuticals","has_results":true},{"nct_id":"NCT05255237","title":"Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":315,"lead_sponsor_name":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","has_results":false},{"nct_id":"NCT07226531","title":"Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06324695","title":"Development and EValuation of an Online Intervention to Reduce Self-Stigma in People With Visible Chronic Skin disEases","phase":"NA","overall_status":"COMPLETED","enrollment_count":298,"lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT07101471","title":"Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation","phase":"","overall_status":"COMPLETED","enrollment_count":296,"lead_sponsor_name":"NanoAlvand","has_results":false},{"nct_id":"NCT07459933","title":"Topical Methotrexate vs Minoxidil for Localized Alopecia Areata","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":268,"lead_sponsor_name":"Jinnah Postgraduate Medical Centre","has_results":false},{"nct_id":"NCT06471114","title":"Evaluation of the Efficacy of Systemic Treatments for Alopecia (ESTAA)","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT07029711","title":"A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07046039","title":"The Impact of Untreated Depression and Anxiety Among Patients With Skin Diseases in Jeddah, Saudi Arabia.","phase":"","overall_status":"COMPLETED","enrollment_count":215,"lead_sponsor_name":"King Abdulaziz University","has_results":false},{"nct_id":"NCT05496426","title":"A Study of KL130008 in Adults With Severe Alopecia Areata","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":176,"lead_sponsor_name":"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.","has_results":false},{"nct_id":"NCT06444451","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":166,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT04445363","title":"A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":160,"lead_sponsor_name":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","has_results":false},{"nct_id":"NCT06402630","title":"A Phase 2 Placebo Controlled, Clinical Trial Designed to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":158,"lead_sponsor_name":"Soterios Ltd","has_results":false},{"nct_id":"NCT06562894","title":"Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":156,"lead_sponsor_name":"CSPC Ouyi Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06573593","title":"Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT03137381","title":"Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":149,"lead_sponsor_name":"Concert Pharmaceuticals","has_results":true},{"nct_id":"NCT02974868","title":"Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":142,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07029828","title":"A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":140,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07311564","title":"A Study of LAD603 in Adults With Alopecia Areata","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":136,"lead_sponsor_name":"Almirall, S.A.","has_results":false},{"nct_id":"NCT03354637","title":"A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":129,"lead_sponsor_name":"Aclaris Therapeutics, Inc.","has_results":true},{"nct_id":"NCT05098600","title":"The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic","phase":"","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"Faculty Hospital Kralovske Vinohrady","has_results":false},{"nct_id":"NCT07200128","title":"A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings","phase":"","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07455708","title":"Impact of NR3C1 rs41423247 (BclI) Polymorphism on Disease Severity in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Benha University","has_results":false},{"nct_id":"NCT07454876","title":"Association of TLR7 Gene rs3853839 Polymorphism With Disease Severity in Alopecia Areata: A Case-Control Study","phase":"","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Benha University","has_results":false},{"nct_id":"NCT06545110","title":"Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"South Valley University","has_results":false},{"nct_id":"NCT04034134","title":"Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":111,"lead_sponsor_name":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","has_results":false},{"nct_id":"NCT03240627","title":"Efficacy and Safety of LH-8 in Paediatric Alopecia Areata","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"Legacy Healthcare SA","has_results":false},{"nct_id":"NCT04680234","title":"Superficial Cryotherapy Versus Microneedling in Alopecia Areata","phase":"NA","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Sohag University","has_results":false}],"total":50},"guidelines":[{"drug_id":"litfulo","guideline_body":"FDA label","recommendation":"LITFULO is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"baricitinib","guideline_body":"FDA label","recommendation":"Baricitinib is indicated for the treatment of adult and pediatric patients 2 years of age and older with moderate to severe alopecia areata.","line_of_therapy":"any","evidence_grade":"B","guideline_year":null},{"drug_id":"baricitinib","guideline_body":"FDA label","recommendation":"Baricitinib is indicated for the treatment of adult and pediatric patients 12 years of age and older with moderate to severe atopic dermatitis who are candidates for systemic therapy.","line_of_therapy":"2L","evidence_grade":"B","guideline_year":null},{"drug_id":"baricitinib","guideline_body":"FDA label","recommendation":"Baricitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.","line_of_therapy":"2L","evidence_grade":"B","guideline_year":null}],"source":"Drug Landscape verified database"}